Biogen Receives Priority Review Status from Japan for Alzheimer’s Drug Developed with Eisai.
February 5, 2023
Trending News 🌥️
Biogen Inc ($NASDAQ:BIIB). is a biotechnology company that focuses on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company’s portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and spinal muscular atrophy. It has operations in the United States, Europe, Canada, and Asia. Recently, Biogen Inc. has received priority review status from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Alzheimer’s drug developed in collaboration with Eisai. The priority review status granted by the MHLW means that the drug will be reviewed in a shorter time frame than other applications.
This is significant as it could potentially expedite the availability of the drug to patients in Japan suffering from Alzheimer’s disease. It also reflects the high level of confidence the Japanese authorities have in the efficacy of the drug and its ability to address an unmet medical need. The partnership between Eisai and Biogen has been instrumental in developing this innovative treatment for Alzheimer’s disease, and their efforts in achieving priority review status is an important milestone. With this approval, Biogen and Eisai have taken an important step towards making an effective therapy available to those suffering from this condition.
Market Price
Monday saw the stock of Biogen Inc. open at $287.4, only to close at $285.9 – a drop of 1.4% from the previous day’s closing price of $290.1. This drug is known as Aducanumab and is an anti-amyloid beta antibody. It is the first drug to receive priority review designation in Japan, and this is a major milestone for the company. This designation is commonly granted to drugs that present a significant improvement over existing treatments for serious conditions. The priority review designation is an important step forward for Biogen and Eisai, as it will help speed up the review process and could potentially lead to the drug being approved earlier than expected. The two companies are hoping that this drug will be a breakthrough treatment for Alzheimer’s disease, a condition that affects millions of people worldwide and currently has no cure. The news of the priority review status is likely to be welcomed by investors, as it could result in increased revenues and profits for Biogen Inc.
However, the stock price dropped slightly on Monday as investors took a more cautious approach to the news. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biogen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 10.36k | 2.86k | 23.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biogen Inc. More…
| Operations | Investing | Financing |
| 2.4k | 1.6k | -1.73k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biogen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 24.85k | 12.09k | 88.72 |
Key Ratios Snapshot
Some of the financial key ratios for Biogen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -10.0% | -24.3% | 35.2% |
| FCF Margin | ROE | ROA |
| 21.0% | 18.5% | 9.2% |
VI Analysis
BIOGEN INC is a company that can be easily evaluated for its long-term potential with the help of the VI app. The app provides an easy-to-understand overview of the company’s fundamentals, allowing investors to make informed decisions. According to the VI Star Chart, BIOGEN INC has a high health score of 10/10 with regard to its cashflows and debt, meaning it has a strong financial position and is capable of safely riding out any crisis without the risk of bankruptcy. In terms of profitability, the company is rated as strong, while its asset and dividend ratings are medium and weak, respectively. Furthermore, BIOGEN INC is classified as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. This makes BIOGEN INC an attractive investment option for a wide range of investors.
Those who are risk-averse may appreciate the company’s strong financial position, while those with a long-term view may be enticed by its potential for growth. Investors looking for a steady stream of income may also be interested in the company as it can offer a steady dividend. In conclusion, BIOGEN INC is a company that can be easily evaluated for its long-term potential with the help of the VI app. It has a strong financial position and offers potential for growth and income, making it an attractive investment option for a wide range of investors.
Peers
In the biotechnology industry, Biogen Inc is up against some stiff competition from the likes of Eli Lilly and Co, Gilead Sciences Inc, and Intra-Cellular Therapies Inc. All three companies are leaders in the development of innovative treatments and therapies for a variety of diseases and disorders. Biogen Inc has developed a reputation for being a cutting-edge company that is constantly striving to bring new and improved treatments to market. This commitment to innovation has allowed Biogen Inc to maintain a strong position in the industry, despite the challenges posed by its competitors.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a global pharmaceutical company that develops and markets prescription medicines and vaccines for various medical conditions. The company’s market cap as of 2022 is 316.18B. Its return on equity (ROE) is 45.88%.
Eli Lilly and Co was founded in 1876 and is headquartered in Indianapolis, Indiana, United States. The company operates in more than 140 countries worldwide. Some of its products include treatments for diabetes, cancer, Alzheimer’s disease, and psychiatric disorders.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercialises innovative therapeutics. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead Sciences Inc has a market cap of 83.2B as of 2022 and a Return on Equity of 24.03%. The company’s products include antiviral therapies, treatments for cancer and inflammatory diseases.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
Intra-Cellular Therapies Inc is a clinical stage biopharmaceutical company that focuses on the development of drugs for the treatment of neuropsychiatric disorders. The company’s market cap as of 2022 was 4.47B, and its ROE was -42.76%. The company’s products are in various stages of development, and include candidates for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Summary
Biogen Inc. recently received Priority Review Status from Japan for an Alzheimer’s drug developed in collaboration with Eisai. This is an important development for Biogen, as the drug has the potential to be a major revenue generator for the company. Investors should take this into consideration when making decisions about investing in Biogen Inc. Shares of Biogen have seen a steady increase since the news, indicating that investors are bullish on the stock. With a strong pipeline of drugs and promising collaborations, Biogen Inc. looks like a good investment opportunity for investors with a long-term strategy.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
